CTOs on the Move

DentalPlans.com

www.dentalplans.com

 
DentalPlans.com connects individuals, families and groups to savings on dental care procedures, with or without dental insurance. Visitors of DentalPlans.com can compare plans by ZIP code or procedure, view sample savings and find a nearby dentist. The company offers more than 30 Dental Savings Plans from trusted networks available at more than 100,000 participating dentists across the country. As the leading online provider, DentalPlans.com is devoted to improving oral health by making quality dental care affordable and accessible to everyone nationwide.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

MacConnell Research

MacConnell Research Corp. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IC Sciences Corporation

IC Sciences Corporation is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gurwin Jewish Nursing and Rehabilitation Center

Gurwin Jewish Nursing and Rehabilitation Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Gurwin Jewish Nursing and Rehabilitation Center is based in Commack, NY. You can find more information on Gurwin Jewish Nursing and Rehabilitation Center at www.gurwin.org

isogenix

isogenix is a Chandler, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kite Pharma

Kite Pharma, founded in 2009, is dedicated to the development and commercialization of novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to fight tumor cells. Kite’s lead programs are in collaboration with the National Cancer Institute (NCI) and are being studied through the NCI’s Surgery Branch led by Steven A. Rosenberg, MD, PhD, who has pioneered immunotherapy approaches for cancer for more than two decades. This research has resulted in breakthrough clinical findings, including results from an NCI Phase 1/2a trial being presented at this year’s American Society of Hematology (ASH) Annual Meeting. Based on this progress and momentum, Kite plans to initiate a company-sponsored multicenter clinical program in aggressive non-Hodgkin’s lymphoma, with additional filings expected for other eACT™ products in diverse oncology indications.